GI
CASC

Gradient Investments’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Gradient Investments’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-44
Closed – – 1237
2017
Q4 		$0 Buy
+44
New +$180 ﹤0.01% 1129

Gradient Investments's CASC Position: Q1 2018 in Review

Gradient Investments sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 44 shares.

Gradient Investments first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Gradient Investments reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Gradient Investments sold 44 Cascadian Therapeutics, Inc. shares in Q1 2018.
  • Gradient Investments first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Gradient Investments's Cascadian Therapeutics, Inc. position peaked at $0 in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Gradient Investments's 13F filing for Q1 2018, filed 11 Apr 2018.